Literature DB >> 17202314

Flt3 is dispensable to the Hoxa9/Meis1 leukemogenic cooperation.

Ester Morgado1, Stéphanie Albouhair, Catherine Lavau.   

Abstract

HOX genes, MEIS1, and FLT3 are frequently up-regulated in human myeloid leukemias. Meis1 cooperates with Hox genes to induce leukemias in mice, hypothetically the consequence of Meis1-induced Flt3 overexpression. To test this, we compared the properties of Flt3(-/-) and Flt3(+/+) progenitors transduced with Hoxa9 or Hoxa9/Meis1. In a myeloid clonogenic assay, Meis1 greatly enhanced the proliferation of Hoxa9-expressing cells, massively up-regulating Flt3 protein. However, the transforming potential of Hoxa9/Meis1 was unaltered in Flt3(-/-) cells. All mice that received Hoxa9/Meis1-transduced progenitors succumbed to rapid acute myeloid leukemias regardless of Flt3 genotype. Flt3 expression levels in leukemic blasts did not correlate with parameters reflecting their proliferative rate or their impaired differentiation. Furthermore, analysis of c-Myb expression levels in Hoxa9/Meis1-transformed cells showed that the up-regulation of this critical downstream effector was independent of Flt3. Altogether, our findings demonstrate that Flt3 is dispensable to the oncogenic cooperation of Meis1 with Hoxa9.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17202314     DOI: 10.1182/blood-2006-01-039586

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

1.  Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity.

Authors:  Chinavenmeni S Velu; Aditya Chaubey; James D Phelan; Shane R Horman; Mark Wunderlich; Monica L Guzman; Anil G Jegga; Nancy J Zeleznik-Le; Jianjun Chen; James C Mulloy; Jose A Cancelas; Craig T Jordan; Bruce J Aronow; Guido Marcucci; Balkrishen Bhat; Brian Gebelein; H Leighton Grimes
Journal:  J Clin Invest       Date:  2013-12-16       Impact factor: 14.808

2.  Isolated Hoxa9 overexpression predisposes to the development of lymphoid but not myeloid leukemia.

Authors:  Sarah H Beachy; Masahiro Onozawa; Deborah Silverman; Yang Jo Chung; Mariela Martinez Rivera; Peter D Aplan
Journal:  Exp Hematol       Date:  2013-02-19       Impact factor: 3.084

Review 3.  Gfi1-cells and circuits: unraveling transcriptional networks of development and disease.

Authors:  James D Phelan; Noah F Shroyer; Tiffany Cook; Brian Gebelein; H Leighton Grimes
Journal:  Curr Opin Hematol       Date:  2010-07       Impact factor: 3.284

4.  MEIS1-mediated transactivation of synaptotagmin-like 1 promotes CXCL12/CXCR4 signaling and leukemogenesis.

Authors:  Takashi Yokoyama; Mayuka Nakatake; Takeshi Kuwata; Arnaud Couzinet; Ryo Goitsuka; Shuichi Tsutsumi; Hiroyuki Aburatani; Peter J M Valk; Ruud Delwel; Takuro Nakamura
Journal:  J Clin Invest       Date:  2016-03-28       Impact factor: 14.808

5.  A CALM-derived nuclear export signal is essential for CALM-AF10-mediated leukemogenesis.

Authors:  Amanda E Conway; Paula B Scotland; Catherine P Lavau; Daniel S Wechsler
Journal:  Blood       Date:  2013-03-13       Impact factor: 22.113

6.  HOX proteins and leukemia.

Authors:  Kajal V Sitwala; Monisha N Dandekar; Jay L Hess
Journal:  Int J Clin Exp Pathol       Date:  2008-03-30

Review 7.  The molecular biology of mixed lineage leukemia.

Authors:  Robert K Slany
Journal:  Haematologica       Date:  2009-06-16       Impact factor: 9.941

8.  Upregulation of Flt3 is a passive event in Hoxa9/Meis1-induced acute myeloid leukemia in mice.

Authors:  A Staffas; L S Arabanian; S Y Wei; A Jansson; S Ståhlman; P Johansson; L Fogelstrand; J Cammenga; F Kuchenbauer; L Palmqvist
Journal:  Oncogene       Date:  2016-09-12       Impact factor: 9.867

9.  Differential requirement for wild-type Flt3 in leukemia initiation among mouse models of human leukemia.

Authors:  Kenjiro Kamezaki; Larry L Luchsinger; Hans-Willem Snoeck
Journal:  Exp Hematol       Date:  2013-11-20       Impact factor: 3.084

10.  Flt3 does not play a critical role in murine myeloid leukemias induced by MLL fusion genes.

Authors:  Stéphanie Albouhair; Ester Morgado; Catherine Lavau
Journal:  PLoS One       Date:  2013-08-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.